- Home
- JCSE vs APVO Comparison
JCSE vs APVO Comparison
Compare JCSE & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JCSE
- APVO
- Stock Information
- Founded
- JCSE 1999
- APVO 2016
- Country
- JCSE Singapore
- APVO United States
- Employees
- JCSE N/A
- APVO N/A
- Industry
- JCSE Miscellaneous manufacturing industries
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- JCSE Consumer Discretionary
- APVO Health Care
- Exchange
- JCSE Nasdaq
- APVO Nasdaq
- Market Cap
- JCSE 5.9M
- APVO 4.1M
- IPO Year
- JCSE 2022
- APVO N/A
- Fundamental
- Price
- JCSE $1.03
- APVO $2.95
- Analyst Decision
- JCSE
- APVO Strong Buy
- Analyst Count
- JCSE 0
- APVO 1
- Target Price
- JCSE N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- JCSE 7.7K
- APVO 6.7M
- Earning Date
- JCSE 05-15-2025
- APVO 08-07-2025
- Dividend Yield
- JCSE 8.61%
- APVO N/A
- EPS Growth
- JCSE N/A
- APVO N/A
- EPS
- JCSE 0.00
- APVO N/A
- Revenue
- JCSE $14,126,397.00
- APVO N/A
- Revenue This Year
- JCSE N/A
- APVO N/A
- Revenue Next Year
- JCSE N/A
- APVO N/A
- P/E Ratio
- JCSE $224.05
- APVO N/A
- Revenue Growth
- JCSE 6.92
- APVO N/A
- 52 Week Low
- JCSE $0.70
- APVO $2.81
- 52 Week High
- JCSE $2.39
- APVO $485.37
- Technical
- Relative Strength Index (RSI)
- JCSE 38.49
- APVO 34.41
- Support Level
- JCSE $1.02
- APVO $2.89
- Resistance Level
- JCSE $1.20
- APVO $3.20
- Average True Range (ATR)
- JCSE 0.04
- APVO 0.23
- MACD
- JCSE -0.01
- APVO 0.23
- Stochastic Oscillator
- JCSE 12.72
- APVO 6.00
About JCSE JE Cleantech Holdings Limited
JE Cleantech Holdings Ltd is engaged in the manufacturing and selling of cleaning systems and other equipment that can be categorized into four different categories, namely aqueous washing systems, plating and cleaning systems, train cleaning systems, and other equipment, such as filtration units. The product lives of its cleaning systems and other equipment ranges from two to ten years. The company is also into designing, developing, and manufacturing other cleaning systems for various industrial end-use applications using its R&D and engineering capabilities. The company derives the majority of its revenue from the Sales of cleaning systems and other equipment. Geographically, the company derives a majority of its revenue from Singapore, followed by Malaysia.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.